Turnstone Biologics Corp - TSBX Net earnings per share for the last four quarters

Official company branding of Turnstone Biologics Corporation (TSBX)

Turnstone Biologics (TSBX) is implementing robotic genome screening to accelerate drug synthesis, leveraging a substantial capital reserve to develop cancer vaccines. The annual EPS growth rate over the last 12 months reflects profit dynamics, where the value of serves as the current metric. Growth prospects are driven by a unique TIL-cell selection method and the test results of the TIDAL-01 drug in partnership with global clinics.

Turnstone Biologics Corp. (TSBX) Earnings per share for the last twelve months: for the period 07/04/2022 - 11/17/2026

TSBX (Turnstone Biologics Corp): analytical breakdowns and indicator data

Initial company analysis:TSBX, Turnstone Biologics
Mass-produced product of Turnstone Biologics Corp.

Turnstone Biologics investments in a staff of specialized oncologists and grant support determine the expenditure structure during early-stage testing. The rolling year earnings per share trend, reaching , measures the efficiency of cash flow regeneration and the ability to cover liabilities. The analyst utilizes this metric to assess the pace of business recovery following a downturn. Growth in EPS TTM allows for the differentiation of real profitability from accounting adjustments. Monitor the annual EPS TTM increase to verify the speed of the issuer's financial recovery.

Direct competitors

Earnings per share for the trailing year IBRX (ImmunityBio)|IMCR: Net earnings per share (EPS TTM)|JANX - Net earnings per share for the last four quarters|Earnings per share for the last twelve months arcusbio.com|Net earnings per share for the last 12 months zymeworks.com (ZYME)|Earnings per share for the last twelve months Tango Therapeutics Inc (TNGX)|Net earnings per share for the last 12 months Iovance IOVA|Immatics NV - Net earnings per share for the last 12 months|Net earnings per share (EPS TTM) Xencor Inc. XNCR|CMPX - Earnings per share for the last twelve months|REPL (replimune.com) - Earnings per share for the last 12 months|Lyell Pharma (LYEL) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Innate Pharma, S.A. (IPHA)|Net earnings per share for the last 12 months PYXS|CGEN - Net earnings per share for the trailing year|Net earnings per share for the last 12 months IOBT (IO Biotech Corp)|Earnings per share for the last four quarters STRO|Net earnings per share (EPS TTM) INKT (MiNK Therapeutics)|Earnings per share for the trailing year HOWL|Immix - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months ALX Oncology Holdings Inc.|CUE: Net earnings per share (EPS TTM)|PDS Biotech - Earnings per share for the trailing year|SONN (Sonnet BioTherapeutics Holdings Inc.) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) MAIA Biotech|Earnings per share for the last twelve months Liminatus Pharma LLC (LIMN)|LVTX: Earnings per one share for the last 12 months|NextCure Inc - Net earnings per share for the last 12 months|Leap Therapeutics, Inc. (LPTX) - Net earnings per one share for the last twelve months|Intensity Therapeutics Inc - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters senseibio.com SNSE|TOVX: Net earnings per share (EPS TTM)|Gritstone bio Inc. - Earnings per share for the trailing year|Net earnings per share for the last 12 months KA|Earnings per share for the last 12 months NEXI (NexImmune, Inc.)|Net earnings per share (EPS TTM) VCNX|HARP: Earnings per one share for the last 12 months